Allay Therapeutics scores $60m Series C

Allay Therapeutics, a clinical-stage biotechnology company, has raised $60 million in Series C financing.

Allay Therapeutics, a clinical-stage biotechnology company, has raised $60 million in Series C financing. Arboretum Ventures led the round with participation from NEA, Temasek, Pavilion Capital, Brandon Capital Partners, Vertex Growth, Vertex Ventures HC and WTT Investment Ltd.

Source: Press Release